Skip to content
OccuflowBIO
01publications

Selected peer-reviewed research underlying OF-01.

A representative selection of the published evidence base, spanning mechanism, therapeutic validation, and the individual chaperone components, that establishes the scientific foundation of the platform.

2021

Sustained activation of the unfolded protein response induces trabecular meshwork dysfunction

Investigative Ophthalmology & Visual Science
2019

Chemical chaperones reduce endoplasmic reticulum stress and restore outflow facility in glaucomatous trabecular meshwork

Scientific Reports
2017

Tauroursodeoxycholic acid reduces ER stress and myocilin misfolding in trabecular meshwork cells

Molecular Vision
2014

4-Phenylbutyrate rescues mutant myocilin trafficking and reduces ER stress in glaucoma

Human Molecular Genetics
2012

Endoplasmic reticulum stress in trabecular meshwork cells and its implications for glaucoma

Progress in Retinal and Eye Research
2010

Myocilin mutations and protein misfolding in the pathogenesis of glaucoma

Experimental Eye Research
2008

The unfolded protein response in ocular homeostasis and disease

Experimental Eye Research
2006

Trabecular meshwork cellular stress response and outflow resistance

Journal of Glaucoma
Representative selection. Full publication record available on request.
OccuflowBIO

A preclinical-stage ophthalmic biotechnology company developing OF-01 to restore the eye's natural drainage architecture in glaucoma.

contact
  • gzode@hs.uci.edu
  • mike@octaneoc.org
  • 505(b)(2) regulatory pathway
investigational product disclaimer

OF-01 is an investigational new drug candidate. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority and has not been demonstrated to be safe or effective for any use. All data described on this website are preclinical. Information provided is for scientific, corporate, and qualified-investor purposes only and is not medical advice.

important disclosures

Preclinical Data: Results described are from in vitro, ex vivo human donor tissue, and animal models, some unpublished. Preclinical findings do not reliably predict results in humans.

Forward-Looking Statements: Statements on development plans, regulatory pathway, timelines, and potential outcomes are forward-looking and subject to substantial uncertainty.

No Offer of Securities: This website is not an offer to sell or a solicitation to buy any security.

No Third-Party Endorsement: Universities and institutions named (including UC Irvine) are identified for background only and do not endorse OccuFlow Bio or OF-01.

© 2026 OccuFlow Bio. All rights reserved.
PRECLINICAL · OF-01 · OPHTHALMOLOGY

Research conducted at UC Irvine (no endorsement implied). OF-01 is an investigational product. Safety and efficacy have not been established.